focus gilead sciences annual report gilead sciences annual report gilead sciences inc lakeside drive foster city california gilead sciences biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need company mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california gilead operation north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead science gilead logo design hepsera letairis ranexa truvada viread vistide volibris register trademark gilead sciences inc relate company atripla register trademark bristolmyer squibb gilead sciences llc lexiscan register trademark astella llc tamiflu register trademark hoffmannla roche inc macugen register trademark eyetech inc wwwgileadcom prescribe information gilead product available wwwgileadcomour focus organization individual work site country world share common focus advance discovery development delivery new medication people worldwide silvia picture cover annual report live hiv story inspire adrian ray phd principal scientist drug metabolism swami swaminathan phd vice president structural chemistry dedicate researcher gilead help advance therapy hivaid lifethreatening condition nosellot ngise gilead gilead derek spencer cnrp executive director jacques initiative institute human virology university maryland school medicine derek spencer nurse practitioner baltimore native recognize provide comprehensive care engage community confront hivrelate stigma help address epidemic city derek colleague establish jacques initiative multidisciplinary holistic healthcare program focus integrate outreach screen linkage care treatment retention gilead work lab clinic help create treatment option patient healthcare professional like derek hongmei director biology gilead science transform treatment forge partnership single tablet regimen hiv atripla introduce work develop effective alloral regimen collaboration kind department gilead therapeutic area oncology example initiate multi help transform treatment disease pill require burdensome interferon injection external partner enhance ability develop year research agreement yale university search patient hiv medication dose deliver new product multiple therapeutic area genetic basis underlie molecular mechanism formulation expert like mark lauren apply scientific increase convenience reduce risk resistance lab field crossfunctional team work form cancer investment earlystage research today expertise challenging process combine multiple medica develop component multidrug regiman innovate aspect business gilead chemistry hold potential yield urgently need targeted cancer tion single tablet work gilead ongoing miss year later introduce second single tablet biology team work share information lab treatment future effort safe effective medicine simple regimen complera work approval hallway identify design new molecule richard lifton phd sterling professor genetic internal antiretroviral product quad mark menne senior research scientist formulation process development medicine chairman department genetics yale university director yale center gilead sciences lauren wiser research scientist formulation process work external organization advance research human genetics genomics investigator howard hughes medical institute concept complete regimen oncedaily tablet development gilead sciences development manufacture product tim pigot senior director marketing gilead sciences louisa leung associate longterm goal treatment hepatitis director market access reimbursement gilead science expand access stay connect recognize people benefit hiv focus program work hiv screening employee hiv therapeutic specialist marta help provider understand profile role gilead therapy diagnose medical care able routine urban community united states reach medical professional eastern europe product feedback receive ongoing afford treatment help change gilead support screen develop world international access program gilead new location warsaw gilead need patient help inform shape gilead educa initiative provide assistance program help patient provide hiv treatment million people grow team european region generate nearly tional program world access medication steep discount mid announce fiveyear percent company annual revenue marta debniaklatuszynska therapeutic specialist gilead sciences donation ambisome world health organization take immediate action grow wait list marta meet provider regularly discuss therapeutic treat patient visceral leishmaniasis aids drug assistance program jeopardize patient access advance field hiv information share deadly parasitic disease hiv medicine country institute additional mother child uganda dayansky anez gloria lamprea nurse rebate antiretroviral product expand urban health plan huy pham manager manufacturing gilead science gilead silvia hiv advocate silvia bear rome italy young family year old diagnose hiv remember time fear isolation london live silvia introduce network hivpositive woman support encouragement help appreciate inner strength today silvia work local advocacy organization positively help hivpositive woman man find voice let let hiv limit support treatment care live live dignity achieve dream silvia mark gilead anniversary stockholder confident innovation integrity hard work allow employee friend great progress year come john martin phd chairman chief executive officer past year exciting focus science period gilead nearly year history gilead pursue science goal transform closed annual revenue treatment lifethreatening disease research billion commercial product development effort large bust pipeline therapeutic area phase clinical study evalu ate compound potential diverse experience background generation innovative therapy hiv hepa titis respiratory cardiovascular metabolic spective contribution employee condition cancer inflammation come different form support discovery new compound design clini november announce acquisition cal trial enhance manufacturing process pharmasset bring oral prepare regulatory submission oversee hepatitis compound phase clinical trial expand exist hepatitis pipeline goal e commercial launch new product transform standard care patient individually employee focus achieve hepatitis deliver alloral regiman elimi excellence designate role nate need weekly injection interferon share focus acquisition pharmasset significantly accelerate pace deliver goal bring new medication area integrate phase study meet medical need patient world program leave right kevin young cbe executive vice president commercial operation robin washington senior vice president chief financial officer norbert bischofberg phd executive vice president research development chief scientific officer john martin phd chairman chief executive officer see record revenue atripla truvada ranexa letairis cayston ambisome gregg alton executive vice president corporate medical affairs kristen metza senior vice president human resources john milligan phd president chief operating officer important new dataset emerge define clinical profile market product investigational compound acquisition calistoga pharmaceuticals inc august food drug administra important progress year inve potential use truvada prevent infection arresto bioscience inc addition research tion fda approve complera second single tigational agent novel prodrug tenofovir atrisk hivnegative individual approach know partnership yale solid foundation tablet regimen hiv addition product small dose enable single tablet preexposure prophylaxis prep base oncology enter phase trial approve europe eviplera november regimen hiv drug currently possible result multinational study conduct evaluate phase midst launch regiman include regimen develop gilead government academic institution gilead sub study myelofibrosis pancreatic cancer colon european country product collaboration company mitte regulatory filing fda december cancer recent purchase biologic manufac example november announce partnership approval oncedaily truvada reduce risk ture facility oceanside california bring new additionally complete phase study develop single tablet regiman combine janssen hiv infection uninfected adult expertise antibody manufacturing support hiv help advance new oncedaily single darunavir emtriva cobicistat ability produce clinical supply tablet regimen october november field chronic hepatitis virus hbv infec potential future product candidate file european approval quad piv landmark study know hptn tion important fiveyear datum present late nership yale focus help discover otal trial product enrol patient provide additional evidence antiretroviral therapy show viread treatment lead new target cancer therapy scientist work take place site continent role treat hiv pre reduction liver fibrosis reversal cirrhosis search genetic basis underlie team work diligently complete study vent transmission result show hivinfecte affect million people worldwide molecular mechanism form cancer submit quad data regulatory authority people begin treatment immediately chronic hbv remain significant global challenge record time week patient visit percent likely transmit virus uninfected focus treatment comprise component viread emtriva partner compare delay starting treat cardiovascular disease investigate truvada boost agent cobicistat ment datum prompt public health expand use ranexa establish therapy important new dataset emerge integrase inhibitor elvitegravir quad single tablet expert universal offer treatment stable chronic angina november define clinical profile market regiman contain integrase inhibitor people hiv immediately diagnosis initiate multicountry phase trial partner product investigational compound prepare launch product united local health department adopt ship cardiovascular research foundation state quarter policy additionally new datum emerge evaluate ranexa angina patient incomplete august fda approve complera second single tablet regimen hiv gilead focus pursue science goal transform treatment lifethreatening disease gilead access program reach million develop world patient represent onequarter patient hiv treatment worldwide revascularization follow percutaneous coronary inter reduce burden obtain test result prior threequarter patient access program endemic area develop world ambisome vention pci patient population risk repeat give monthly prescription follow take generic version gilead product produce commercially available year hospitalization procedure study change letairis sale increase percent indian manufacturing partner july continue address significant unmet medical determine addition ranexa standard expand agreement indian need systemic fungal infection result therapy reduce rate major adverse cardiovas finally initiate phase study evaluate partner include future right manufacture dedicated effort team europe cular event addition evaluate cystic fibrosis therapy cayston treatment pipeline product include quad regula ambisome revenue grow percent ranexa treat patient coro infection noncf bronchiectasis obstructive tory approval expand agreement permit million worldwide nary artery disease diabetes define lung disease airways damage time sale generic viread potential benefit initiate phase study infection lead poor airflow preliminary result treatment hepatitis july gilead united states continue support ranexa january type diabete expect company join medicine patent pool patient assistance program provide medicine organization establish facilitate expand therapeutic area cost lowincome focus effort employee organiza focus access access hiv treatment develop world uninsured patient copay assistance program tion research commercial drug safety regulatory sharing patent help unable afford insurance copay medical affair team help achieve important important develop new product milestone letairis treatment pulmonary help fight neglect tropical disease visceral focus result ensure product available patient arterial hypertension march fda agree leishmaniasis product donation worth need gilead access program remove boxed warning potential risk reach million develop world million world health organization gilead generate product sale liver injury letairis base collection patient represent onequarter patient december affect half million billion percent increase patient year postmarkete datum hiv treatment worldwide people year leave untreated majority revenue drive continue datum collect gilead labsync program fatal gilead provide nearly success atripla truvada mostpre change mean letairis patient long vial ambisome year treat scribed hiv regimen product respectively require undergo monthly liver monitor patient support control effort united states major european country achieve record market share combine hiv portfolio cardiopulmonary product gilead product available country world financial highlight product sale total revenue million millions ranexa letairis ambisome antiviral franchise cardiovascular respiratory product pro thank employee reach million vide large percentage revenue people worldwide lifesave medicine increase percent mark gilead anniversary confident innovation integrity hard like acknowledge guidance work allow great progress earning share operate cash flow board director member scien year come thank continue million tific medical advisory board provide support gilead science expertise help achieve accomplishment sincerely john martin phd chairman chief executive officer gaap dilute earning share nongaap dilute earning share forwardlooke statement nongaap dilute earning share exclude aftertax impact acquisitionrelate expense aftertax impact restructuring expense aftertax impact stockbase compensation expense annual report contain forwardlooke statement clinical study product candidate include anticipated enrollment completion date certain clinical trial potential product candidate include anticipate regulatory approval launch statement prediction involve risk nongaap dilute earning share exclude aftertax impact acquisitionrelate expense aftertax impact restructuring expense aftertax impact stockbase compensation expense uncertaintie actual result differ materially refer gilead annual report year end december attach report nongaap dilute earning share exclude aftertax impact acquisitionrelate expense aftertax impact restructuring expense aftertax risk uncertainty affect gilead business gilead disclaims undertake obligation update revise forwardlooke statement report impact stockbase compensation expense gilead gilead focus area hiv aids liver disease decade case hiv aid report tremendous chronic hepatitis hepatitis know silent killer slowly advance treatment transform terminal disease manageable damage liver year cause noticeable symptom result chronic condition approval hiv medication viread gilead year nearly million people worldwide die complication associate viral play central role development simplify hiv treatment regimen oncedaily infection coformulate medicine available single tablet research show high adherence hiv medicine critical reduce risk hiv drug resistance treatment failure chronic hepatitis effectively treat therapy like viread gilead new single tablet regimen quad undergo review regulatory agency maintain longterm viral suppression associate reversal liver cirrhosis united states europe united states europe continue support development new commu nitybase awareness campaign encourage hepatitis screen linkage care initiate phase study novel prodrug tenofovir active agent gilead recent expansion asia focus effort educate community viread exhibit great potency human clinical study dose time low disease availability effective treatment option viread viread enable new hiv combination feasible viread addition continue pursue approach limit duration therapy hepatitis ongoing preclinical research evaluate new compound class hiv molecule include oral therapy therapeutic vaccine noncatalytic integrase inhibitor inlicense boehringer ingelheim october patient hepatitis gilead aims develop effective alloral treatment regimen gilead engage earlystage research focus identify novel agent thera eliminate need interferon injectable medicine associate seri peutic strategy role play help eradicate cure hiv infection ous effect acquisition pharmasset lead compound phase clinical trial bring important step close achieving goal exist pipeline hepatitis compound explore combination regimen help address unmet need effective medication easy candidate phase phase phase nucleotide nsb inhibitor hepatitis protease inhibitor hepatitis nsa inhibitor hepatitis protease inhibitor hepatitis nonnucleoside nsb inhibitor hepatitis candidate phase phase phase quad integrase single tablet regimen monoclonal antibody liver fibrosis elvitegraviremtricitabinetenofovir disoproxil fumaratecobicistat hiv aid application submit cobicistat nonnucleoside nsb inhibitor hepatitis pharmacoenhancer hiv aids elvitegravir tlr agonist hepatitis hepatitis integrase inhibitor hiv aids nucleotide reverse transcriptase inhibitor hepatitis nucleotide reverse transcriptase inhibitor hiv aids color imagery page modify gilead cardiovascular metabolic respiratory heart disease remain lead cause death united states world infection genetic factor environmental condition million people suffer accounting quarter death globally gilead focus develop therapy disorder cause breathing difficulty respiratory disease life alleviate symptom improve quality life outcome patient threaten significantly impair patient quality life seasonal influenza cardiovascular condition example cause million case severe illness death globally year gilead strong heritage respiratory arena letairis help improve exercise capacity delay clinical worsen patient pul invent world lead oral antiviral treatment prevention influenza monary arterial hypertension pah incurable cardiovascular disease affect tamiflu commercialize roche people worldwide pah lead heart failure leave untreated ranexa reduce painful chronic angina attack patient return daily activity unlike currently focus provide therapy people cystic fibrosis inherit angina treatment ranexa take wide range heart medica chronic disease affect pulmonary digestive system impact tion help doctor patient develop comprehensive plan manage concurrent people worldwide lung patient particularly susceptible chronic bacterial cardiovascular disease infection call pseudomona aeruginosa treat gilead inhale antibiotic cayston investigate potential treat infection noncf bronchiectasis explore potential ranexa therapy heart metabolic disorder respiratory condition test investigational monoclonal antibody launch new study cardiovascular research foundation assess effi efficacy idiopathic pulmonary fibrosis lifethreatening scar lung cacy add ranexa standard therapy patient angina coronary artery know cause remain partially block follow angioplasty conduct phase study determine ranexa role play treatment type diabetes candidate phase phase phase aztreonam inhalation solution candidate phase phase phase noncf bronchiectasis ranolazine late sodium current inhibitor incomplete revascularization postpci monoclonal antibody idiopathic pulmonary fibrosis ranolazine late sodium current inhibitor type diabete ranolazinedronedarone fixeddose combination paroxysmal atrial fibrillation market product product indication partner oncology inflammation hiv aids atripla hiv aids bristolmyers squibb company efavirenz mgemtricitabine western europe canada tenofovir disoproxil fumarate merck inc rest world significant progress fight cancer recent year novel target therapy design specifically address individual tumor biology drug complera hiv aids emtricitabinerilpivirinetenofovir resistance easily tolerate urgently need disoproxil fumarate truvada hiv aids japan tobacco inc improvement understand cancer genetic allow oncologist define different emtricitabinetenofovir japan type cancer body occur specific disoproxil fumarate molecular characteristic drive cancer evidence specific emtriva hiv aids japan tobacco inc molecular abnormality well treat targeted approach emtricitabine japan pursue potential oncology candidate pik delta inhibitor viread hiv aids japan tobacco inc currently clinical trial certain form leukemia lymphoma tenofovir disoproxil fumarate japan testing monoclonal antibody determine role combat malig nancy include myelofibrosis lifethreatening bone marrow disorder pancreatic cancer liver disease colon cancer addition internal discovery effort partnership viread chronic hepatitis glaxosmithkline inc yale university establish march working identify new molecular tenofovir disoproxil fumarate china japan saudi arabia target develop novel target therapy address cancer base unique molecular characteristic explore syk inhibitor target approach hepsera chronic hepatitis glaxosmithkline inc inflammatory disorder adefovir dipivoxil asia latin america cardiovascular lexiscan coronary vasodilation astellas pharma inc canada regadenoson injection rapidscan europe select market letairis pulmonary arterial hypertension glaxosmithkline inc ambrisentan group outside ranexa chronic angina menarini group ranolazine europe respiratory cayston cystic fibrosis candidate phase phase phase aztreonam inhalation solution pik delta inhibitor chronic lymphocytic leukemia tamiflu influenza hoffmannla roche ltd oseltamivir phosphate worldwide pik delta inhibitor indolent nonhodgkin lymphoma monoclonal antibody myelofibrosis macugen neovascular wet agerelate eyetech inc pegaptanib sodium injection macular degeneration pfizer inc outside monoclonal antibody pancreatic cancer vistide cmv retinitis aid cidofovir injection monoclonal antibody colorectal cancer ambisome severe fungal infection astellas pharma inc canada syk inhibitor rheumatoid arthritis amphotericin liposome injection dainippon sumitomo pharma ltd japan corporate information focus board director senior leadership team robert schooley independent register public john martin phd john martin phd professor medicine head accountant chairman chief executive officer chairman chief executive officer division infectious disease ernst young llp gilead sciences vice chair department medicine palo alto california john milligan phd university california san diego james denny president chief operating officer corporate headquarters gilead sciences annual report lead independent director eric topol gilead sciences inc gilead sciences board director norbert bischofberg phd director scripps translational lakeside drive executive vice president science institute foster city usa john cogan phd research development chief academic officer scripps health senior fellow hoover institution chief scientific officer professor translational genomics wwwgileadcom stanford university scripps research institute gregg alton vicechairman west wireless stockholder inquiry etienne davignon executive vice president health institute inquiry stockholders minister state corporate medical affair potential investor chairman genfina bernard wagner company welcome kevin young cbe emeritus research professor receive prompt response direct carla hill executive vice president pathology new york university request information chair chief executive officer commercial operation medical center hill company international investor relation consultant kristen metza health policy advisory board gilead sciences inc senior vice president sir richard feachem kbe freng lakeside drive kevin lofton human resource dscme phd chairperson foster city usa president chief executive officer director global health group catholic health initiatives robin washington professor global health senior vice president university california san francisco information gilead john madigan chief financial officer university california berkeley available wwwgileadcom retire chairman chief executive officer scientific advisory board seth berkley stock list tribune company joel huff phd chairperson chief executive officer gilead common stock trade retired vice president gavi alliance nasdaq global select stock market gordon moore phd medicinal chemistry symbol gild retire chairman merck research laboratory michael drake chief executive officer chancellor annual meeting intel corporation paul berg phd university california irvine annual meeting stockholder cahill professor hold thursday nicholas moore biochemistry emeritus david gollaher phd westin retire global chairman stanford university school medicine president chief executive officer san francisco airport hotel pricewaterhousecoopers california healthcare institute francis chisari transfer agent registrar richard whitley professor virology immunology calvin pan communication concern stock distinguish professor scripps research institute president transfer requirement lose certificate loeb scholar chair pediatric medical procare pllc change address professor pediatric microbiology peter dervan phd direct transfer agent medicine neurosurgery bren professor chemistry robert shapiro phd university alabama birmingham california institute technology chairman computershare sonecon llc washington boulevard gayle edlund wilson paul klotman jersey city chair ralph parsons foundation president chief executive officer richard whitley usa john clara whitmore distinguish professor woldolsen professor baylor college medicine loeb scholar chair pediatric wwwcomputersharecom retire president human health professor pediatric microbiology intercontinental division john mellors medicine neurosurgery equal opportunity employer merck inc professor medicine university alabama birmingham gilead science proud equal chief division infectious disease opportunity employer extend director emeritus gilead sciences university pittsburgh school woldolsen employment man woman board director medicine retire president human health culturally diverse background george shultz phd intercontinental division environment respect individual distinguish fellow eugene schiff merck inc difference recognize hoover institution leonard miller professor medicine employee integral member stanford university director schiff liver institute corporate secretary company workforce reflect director center liver disease gregg alton value celebrate individual university miami school executive vice president corporate grow team medicine medical affair gilead sciences annual report gilead sciences inc lakeside drive foster city california gilead sciences biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need company mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california gilead operation north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead science gilead logo design hepsera letairis ranexa truvada viread vistide volibris register trademark gilead sciences inc relate company atripla register trademark bristolmyer squibb gilead sciences llc lexiscan register trademark astella llc tamiflu register trademark hoffmannla roche inc macugen register trademark eyetech inc wwwgileadcom prescribe information gilead product available wwwgileadcom focus gilead sciences annual report gilead sciences annual report gilead sciences inc lakeside drive foster city california gilead sciences biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need company mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california gilead operation north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead science gilead logo design hepsera letairis ranexa truvada viread vistide volibris register trademark gilead sciences inc relate company atripla register trademark bristolmyer squibb gilead sciences llc lexiscan register trademark astella llc tamiflu register trademark hoffmannla roche inc macugen register trademark eyetech inc wwwgileadcom prescribe information gilead product available wwwgileadcom